Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 1
Submit an article Journal homepage
180
Views
1
CrossRef citations to date
0
Altmetric
Commentary

Management of induction failures in newly diagnosed transplant-eligible multiple myeloma

Morie A. GertzDivision of Hematology, Mayo Clinic, Rochester, MN, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-3853-5196View further author information
ORCID Icon
Pages 1-3 | Received 16 Aug 2019, Accepted 25 Aug 2019, Published online: 10 Sep 2019

References

  • Blocka J, Hielscher T, Mueller-Tidow C, et al. Salvage therapy versus up-front autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy. Leuk Lymphoma. 2020;61(1):27–36.
  • Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–527.
  • Gertz MA, Kumar S, Lacy MQ, et al. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood. 2010;115(12):2348–2353.
  • Cohen YC, Joffe E, Benyamini N, et al. Primary failure of bortezomib in newly diagnosed multiple myeloma-understanding the magnitude, predictors, and significance. Leuk Lymphoma. 2016;57(6):1382–1388.
  • Lee SE, Yoon JH, Shin SH, et al. Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma. Ann Hematol. 2014;93(4):627–634.
  • Kobayashi T, Kuroda J, Fuchida S, et al. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma. Intern Med. 2013;52(9):961–968.
  • Vij R, Kumar S, Zhang MJ, et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2015;21(2):335–341.
  • Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia. 2014;28(2):258–268.
  • Jackson GH, Davies FE, Pawlyn C, UK NCRI Haemato-oncology Clinical Studies Group, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57–73.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.